SEC Form 4 · accession 0001209191-17-049702
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacques Dumas
Officer — Chief ScientificOfficer
Period of report
Aug 17, 2017
Accepted (ET)
Aug 21, 2017 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 17, 2017 | S | 7,155 | $5.86 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On January 6, 2016, the Reporting person was granted 35,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on June 10, 2016. Of the 2016 RSU grant, 11,667 shares vested on January 6, 2017 of which 4,512 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on the vesting date. The remaining 7,155 shares were sold on August 17, 2017 and such sale is reported on this Form 4.
- F2The sale of these shares of common stock reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $5.79 to $5.90 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.